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The efficacy of anti-TNF-a antibody infliximab in refractory ulcerative colitis: Its positioning among the variety of treatment options Background: Anti-TNF (tumor necrosis factor)-a antibody (infliximab: IFX) is one of rescue options for acute severe steroid-refractory ulcerative colitis (UC). In addition to tacrolimus which was already approved in Japan, IFX was recently approved for clinical use in patients with UC in Japan. In the present study, we evaluate the efficacy and safety of IFX in patients with intractable UC retrospectively. Methods: We analysed 28 patients who were treated with infliximab at Keio University Hospital from June, 2010 through July, 2011. Infliximab (5 mg/kg body weight) was administered at 0, 2, 6 weeks and every 8 weeks thereafter. Indications for IFX were as follows; tacrolimus-failure (tacrolimusrefractory and relapse after tacrolimus therapy), steroidrefractory, steroid-dependent, others (intractable, extraintestinal manifestations). Evaluation of the clinical response was based on a modified Truelove-Witts clinical activity index (CAI). Short-term clinical response was determined at 6 weeks after the start of IFX therapy. Efficacy of maintenance therapy and safety were also evaluated. Results: Overall efficacy of induction therapy was 63.0% (remission: 37.0%, improvement; 26.0%). When looking at indications for infliximab administration, efficacies including remission and improvement were 40.0%, 85.7%, 57.1% and 100% for tacrolimus-failure, steroid-refractory, steroid-dependent and the others, respectively. Efficacy of IFX in patients with history of tacrolimus therapy was 41.7%, which was much lower than in those without tacrolimus (80.0%). Among patients who were administered infliximab as maintenance therapy, 6 of 8 patients who achieved remission with induction therapy remained remission. The rest 2 patients, who had relapsed, achieved remission with re-induction therapy or adjustment of administration schedule. As for safety issue, only one patient developed infusion reaction which required discontinuation of the therapy. Conclusions: Our results suggested that infliximab therapy was safe and effective for induction and maintaining remission of ulcerative colitis refractory to conventional medical treatment, however, its efficacy might be lowered after tacrolimus therapy. Background: Intercellular adhesion molecule are involved not only in the distribution of cells at the periphery but also in the processes of cell interactions in the development of the immune response. In the process of settlement, there are two distinct phases: first phase the interaction of migrating T cells to the endothelium of postcapillary venules and the second stage the passage through the endothelium into the parenchyma of the organ. The implementation of these steps are involved adhesins different molecules: L-selectin, E-selectin, P-selectin, sVCAM-1. They cause the migration of cells from the bloodstream into the inflammatory focus, ie contribute to increased inflammatory infiltration of the mucous membrane and homing of lymphocytes. The activity of endothelial cells and their involvement in the development of inflammation are not less important than the effect of the inflammatory infiltrate cells. Aim: To study the effect of infliximab on the level of adhesion molecules in patients with inflammatory bowel disease (IBD). Methods: We examined 16 patients with IBD receiving infliximab, including 7 patients with ulcerative colitis (UC) and Crohn's disease in 9 patients (CD). Age of patients ranged from 17 to 68 years, mean age 40.3. The diagnosis of UC and BC data confirmed the clinical, laboratory, histological, and instrumental methods. Before and after treatment with Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/6/Supplement_1/S96/370299 by guest on 06 April 2019
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